Product logins

Find logins to all Clarivate products below.


Type 2 Diabetes | Physician & Payer Forum | South Korea and Taiwan | 2014

South Korea and Taiwan have the most advanced healthcare systems among Asian countries, and both operate a universal health insurance program that covers inpatient and outpatient services as well as pharmaceuticals. Both countries have a high level of pharmaceutical expenditure and an increasing awareness of the financial burden associated to type 2 diabetes which presents a significant opportunity for multinational pharmaceutical companies as the demand for novel antidiabetic drugs continues to grow. In this report, we explore the current market access environment for type 2 diabetes in both countries, and physician and payer attitudes and behaviors concerning currently marketed antidiabetic therapies, and their expectations for emerging therapies.

Related Market Assessment Reports

Report
Type 2 Diabetes – Current Treatment – Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis (US)
Metformin remains the most heavily prescribed type 2 diabetes (T2D) drug and dominates the early lines of therapy before disease progression requires insulin replacement. More effective, safer, and…
Report
Type 1 Diabetes – Landscape & Forecast – Disease Landscape & Forecast (G7)
The treatment options for type 1 diabetes (T1D) patients are limited; insulins, pramlintide (in the United States), and sodium-glucose cotransporter-2 (SGLT-2) inhibitors (only in Japan) are the…
Report
Type 2 Diabetes – Current Treatment – Current Treatment: Physician Insights – GLP-1 receptor agonist products (US)
Glucagon-like peptide-1 receptor agonist (GLP-1 RA) products like Novo Nordisk’s semaglutide SC (Ozempic / Wegovy) and Eli Lilly’s tirzepatide (Mounjaro / Zepbound) have gained popularity in…
Report
Type 2 Diabetes – Geographic Focus: China – Type 2 Diabetes – China In-Depth (China)
In China, type 2 diabetes (T2D) continues to be a leading public health concern, with the highest global prevalence. Biguanides continue to dominate the market, but the use of SGLT-2 inhibitors and…
Report
Type 2 Diabetes – Landscape & Forecast – Disease Landscape & Forecast (G7)
The type 2 diabetes (T2D) therapy market will expand through 2033, supported by polypharmacy and growing use of later-line therapies offering nonglycemic benefits. However, the loss of exclusivity…